<DOC>
	<DOCNO>NCT02007356</DOCNO>
	<brief_summary>To assess feasibility donor-derived interferon ( IFN ) -γ positive select-ed virus-specific T-cells use cytokine capture system® ( CCS ) safety subsequent infusion recipient hematopoietic stem cell transplantation ( HSCT ) treatment refractory post-transplant viral infection . The CCS already successfully use clinical study Germany United Kingdom ( UK ) .</brief_summary>
	<brief_title>A Study Assess Safety Feasibility Direct Infusions Donor-derived Virus-specific T-cells Recipients Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using Cytokine Capture System®</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<criteria>Adults &gt; 18 year age Undergone allogeneic HSCT Written inform consent Patients treatment refractory infection adenovirus , cytomegalovirus ( CMV ) EpsteinBarr virus ( EBV ) include case fulfil follow criterion : Patient Adenovirus Infection : 1 . Antiviral treatment cidofovir least 7 day virus load decrease ( ≤ 1 log ) virus load increase treatment least 7 day cluster differentiation 3 ( CD3 ) + cell &lt; 300/µL treatment least 7 day 2 . Or antiviral treatment contraindicate Patient EBV : 1 . After receipt least one anticluster differentiation 20 antigen ( CD20 ) antibody treatment ( 375 mg/m2 ) No Virus load decrease ( ≤ 1 log ) virus load increase 7 day receipt treatment CD3+ cell &lt; 300/µL 7 day receipt treatment Clinical progression Patient CMV : 1 . Antiviral treatment ganciclovir foscavir 14 day No Virus load decrease ( ≤ 1 log ) virus load increase day 14 2 . Or &gt; 2 recurrence despite antiviral treatment ganciclovir foscavir 14 day CD3+ cell &lt; 300/µL 3 . Or antiviral treatment contraindicate Patient graftversushost disease ( GVHD ) &gt; grade 2 time point plan infusion Known allergy irondextran murine antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>